LDN Book, Volume Two

Regular price €28.50
Title
Quantity:
In stock with our UK publisher. 14-28 days
Delivery/Collection within 10-20 working days
14 days return policy Shipping & Delivery
A01=Linda Elsegood
alternative
Author_Linda Elsegood
autoimmune
Category=MJC
Category=MKG
Category=VFJB
diet
eq_bestseller
eq_health-lifestyle
eq_isMigrated=1
eq_nobargain
eq_non-fiction
inflammation
Low Dose Naltrexone
Lyme Disease
nervous system
opioid addiction
pain relief

Product details

  • ISBN 9781603589901
  • Weight: 426g
  • Dimensions: 153 x 229mm
  • Publication Date: 22 Oct 2020
  • Publisher: Chelsea Green Publishing Co
  • Publication City/Country: US
  • Product Form: Paperback
Secure checkout Fast Shipping Easy returns

A comprehensive examination of Low Dose Naltrexone – a little-known drug with big potential

New drug [LDN] raises hopes of reversing memory loss in old age the Guardian

A drug that is simultaneously affordable, devoid of severe side effects, and applicable to a wide range of diseases is not often found in the modern pharmaceutical landscape. But as medical professionals and researchers alike continue to discover, Low Dose Naltrexone (LDN) boasts this remarkable combination.

Expanding on the information presented in The LDN Book, Volume 1 – which showcased LDN’s efficacy in treating conditions such as lupus, thyroiditis, autism spectrum disorder, and chronic fatigue – Volume 2 highlights the latest clinical trials, case studies and research on LDN. More than a dozen medical professionals explain how they are using LDN to help patients suffering from:

  • Chronic pain
  • Parkinson’s disease
  • Dermatologic conditions
  • Traumatic brain injury 
  • Lyme disease and more.

Volume 1 and Volume 2 have been edited by Linda Elsegood, founder of the UK-based LDN Research Trust. Through the Trust and her work on the LDN books, Linda has connected thousands of patients, doctors and pharmacists around the world with information, articles and patient stories about LDN. The LDN Book, Volume 2 is a fantastic resource for practitioners, pharmacists and patients and a renewed call for further research on the healing potential of this beneficial drug.

Linda Elsegood is the founder of the LDN Research Trust, which was set up in the UK as a Registered Charity in 2004, and is the editor of The LDN Book. Diagnosed with MS in August of 2000, she started LDN therapy in December of 2003, and now has a better quality of life and hope for the future. Through the Trust, she has connected thousands of patients, doctors, and pharmacists around the world with information, articles, and patient stories about LDN.

More from this author